Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants - PubMed
a day ago
- #monoclonal antibodies
- #Omicron variants
- #SARS-CoV-2
- Epitope-focused discovery of SARS-CoV-2 antibodies targeting Omicron variants.
- Use of glycan-masked antigens to isolate 303 monoclonal antibodies (mAbs).
- Some mAbs potently neutralize divergent Omicron subvariants by targeting the class 3 antigenic site on the RBD.
- Epitope mapping reveals a spectrum of cross-reactivity and differential recognition.
- Rational design of glycan-masked engineered RBDs for targeted mAb discovery.
- Multiple authors have competing interests, including patents and consulting roles.
- Funding provided by DARPA, NIH, and other U.S. health agencies.